APA (7th ed.) Citation

CN, L., RJ, B., MW, S., RS, M., JL, W., PA, D., . . . MA, B. (2024). Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(21), 2537. https://doi.org/10.1200/JCO.23.02076

Chicago Style (17th ed.) Citation

CN, Landen, et al. "Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 42, no. 21 (2024): 2537. https://doi.org/10.1200/JCO.23.02076.

MLA (9th ed.) Citation

CN, Landen, et al. "Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 42, no. 21, 2024, p. 2537, https://doi.org/10.1200/JCO.23.02076.